Citius Pharmaceuticals (CTXR) Stock Statistics & Valuation Metrics

Citius Pharmaceuticals has a market cap or net worth of $18.69M. The enterprise value is $13.29M.

Citius Pharmaceuticals has 20,762,917 shares outstanding. The number of shares has decreased by -2.65% in one year.

Citius Pharmaceuticals’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is 0.00%.

The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is 0.00.

In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -39.74M in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -20.58M and capital expenditures -4.00, giving a free cash flow of -20.58M billion.

Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Citius Pharmaceuticals upcoming earnings date is Feb 6, 2026, Before Open (Confirmed).

Citius Pharmaceuticals as a current ratio of 0.62, with Debt / Equity ratio of 2.89%

In the past 12 months, Citius Pharmaceuticals has paid 1.06M in taxes.

Citius Pharmaceuticals EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 0.13.

Citius Pharmaceuticals has $6.09M in cash and marketable securities with $1.88M in debt, giving a net cash position of $4.21M billion.

Gross margin is -132.05%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Citius Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―